Search - tctmd.com

Displaying 1 - 20 of 88

Sort: Relevancy | Date

Presentation TCT Abstracts Posters 2018

Comparison of clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation

Presenter: Hyungdon Kook

September 25, 2018

Presentation TCT 2018

LAA Closure: Challenging Case Vignettes

Presenter: Saibal Kar, Horst Sievert, Philippe Garot, Jan Kovac, Ashish Pershad, Ramon Quesada, Peter B. Sick, Brian K. Whisenant

September 24, 2018

Presentation TCT 2018

The Big Picture: Choosing the Right Device for the Right Anatomy

Presenter: Saibal Kar, Horst Sievert

September 24, 2018

Presentation TCT 2018

Epicardial LAA closure: From Surgical Results to Transpericardial Applications

Presenter: Saibal Kar, Horst Sievert, Krzysztof Bartus

September 24, 2018

Presentation TCT 2018

SeaLA: Differentiating Features, Technique and Outcomes

Presenter: Saibal Kar, Horst Sievert

September 24, 2018

Presentation TCT 2018

Cardia: Differentiating Features, Technique and Outcomes

Presenter: Saibal Kar, Horst Sievert, Reda Ibrahim

September 24, 2018

Presentation TCT 2018

Optimal Technique and Tips for Amulet Implantation

Presenter: Saibal Kar, Horst Sievert

September 24, 2018

Presentation TCT 2018

Optimal Technique and Tips for Watchman Implantation

Presenter: Saibal Kar, Horst Sievert

September 24, 2018

Presentation TCT 2018

The Watch TAVR Trial: Rationale, Design and Status

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Samir R. Kapadia

September 24, 2018

Presentation TCT 2018

The WaveCrest Device and US Pivotal Trial

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Gregg W. Stone

September 24, 2018

Presentation TCT 2018

The Amulet Platform, Experience and US Pivotal Trial

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Apostolos Tzikas

September 24, 2018

Presentation TCT 2018

The Watchman Platform, ASAP Too and Flex: Rationale, Device and Overview of the Trials

Presenter: Vivek Y. Reddy, Brian K. Whisenant

September 24, 2018

Presentation TCT 2018

FDA Perspectives on New Devices and Indications for LAA Closure

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Andrew Farb

September 24, 2018

Presentation TCT 2018

The LAAO Registry: Overview, Data Adjudication, and Emerging Insights

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Paul D. Varosy

September 24, 2018

Presentation TCT 2018

Managing a Busy LAA Closure Program: Patient Selection, Education, Consent, Screening, and Periprocedural Care

Presenter: James B. Hermiller Jr, David Hildick-Smith, George S. Hanzel

September 24, 2018

Presentation TCT 2018

Adjunctive Pharmacology Following LAA Closure in Anticoagulant Indicated and Contraindicated Patients

Presenter: James B. Hermiller Jr, David Hildick-Smith, Martin W. Bergmann

September 24, 2018

Presentation TCT 2018

Essential of Pre-procedural Imaging and Intra-procedural Guidance

Presenter: James B. Hermiller Jr, David Hildick-Smith, Jacqueline Saw

September 24, 2018

Presentation TCT 2018

Shared Decision-making in NVAF: The Patients Perspective

Presenter: James B. Hermiller Jr, David Hildick-Smith, Megan Coylewright

September 24, 2018

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients with No or Mild Contraindications to Anticoagulants? Yes - LAA Closure Reduces Hemorrhagic Stroke and Mortality And Nearly Everyone Has a Reason Not to Take Oral Anticoagulants!

Presenter: James B. Hermiller Jr, David Hildick-Smith, David R. Holmes Jr.

September 24, 2018

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Presenter: James B. Hermiller Jr, David Hildick-Smith, Freek W.A. Verheugt

September 24, 2018

Advertisement

Comparison of clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation

LAA Closure: Challenging Case Vignettes

The Big Picture: Choosing the Right Device for the Right Anatomy

Epicardial LAA closure: From Surgical Results to Transpericardial Applications

SeaLA: Differentiating Features, Technique and Outcomes

Cardia: Differentiating Features, Technique and Outcomes

Optimal Technique and Tips for Amulet Implantation

Optimal Technique and Tips for Watchman Implantation

The Watch TAVR Trial: Rationale, Design and Status

The WaveCrest Device and US Pivotal Trial

The Amulet Platform, Experience and US Pivotal Trial

The Watchman Platform, ASAP Too and Flex: Rationale, Device and Overview of the Trials

FDA Perspectives on New Devices and Indications for LAA Closure

The LAAO Registry: Overview, Data Adjudication, and Emerging Insights

Managing a Busy LAA Closure Program: Patient Selection, Education, Consent, Screening, and Periprocedural Care

Adjunctive Pharmacology Following LAA Closure in Anticoagulant Indicated and Contraindicated Patients

Essential of Pre-procedural Imaging and Intra-procedural Guidance

Shared Decision-making in NVAF: The Patients Perspective

Debate: Is LAA Closure a Valid Alternative for Patients with No or Mild Contraindications to Anticoagulants? Yes - LAA Closure Reduces Hemorrhagic Stroke and Mortality And Nearly Everyone Has a Reason Not to Take Oral Anticoagulants!

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content